Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced its participation in several major healthcare conferences from November to December 2026. The company will engage in fireside chats and investor meetings at events including the Stifel Healthcare Conference, Truist BioPharma Symposium, UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, and Piper Sandler Healthcare Conference. These appearances provide Viking an opportunity to update investors on its development programs, including its lead obesity treatment VK2735, currently in Phase 3 trials. Live webcasts of some sessions will be available on Viking's website, allowing broader access to the company's latest progress and strategy.
Viking Therapeutics' participation in upcoming investor conferences comes as the health sector on Pluang shows broad activity, with 92 of 150 priced US health stocks rising today. For readers following health stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: Summit Therapeutics Inc (SMMT) led gains with a 7.09% increase to USD 15.86 and 100% buy order activity, followed by Tango Therapeutics Inc. (TNGX) up 6.48% at USD 23.17, and 10X Genomics Inc (TXG) rising 6.17% to USD 65.43 with a typical hold time of 92 days.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
JELD-WEN Holding, Inc. reported a net loss of $17.2 million in Q3 2026, a significant improvement from a $367.6 million loss a year earlier, driven by tariff refunds, productivity gains, and cost reductions. Net revenues slightly declined by 1.4% to ...
Hormel Foods Corporation will release its fourth-quarter and full-year 2026 financial results on December 3, 2026, before market open. The company will also hold a webcast and conference call at 8 a.m. CT to discuss the results and provide an outlook...
Vanda Pharmaceuticals announced its participation in several key healthcare investor conferences throughout November 2026, including events in New York City and London. The company will hold fireside chats at the Stifel 2026 Healthcare Conference and...
